WNTresearch is a biotechnology company at the forefront of developing a therapy to combat cancer metastasis. Their groundbreaking research is focused on studying the body's own protein, WNT5A, which has been found to affect the ability of tumor cells to move and spread. WNTresearch's flagship pharmaceutical candidate, Foxy-5, is a peptide that mimics the function of WNT5A and is currently undergoing evaluation in the clinical phase 2 study known as NeoFox, involving patients with stage II-III colorectal cancer.

Founded in 2007 and headquartered in Malmö, Sweden, WNTresearch is dedicated to advancing the field of cancer therapeutics and making a meaningful impact on patient outcomes. With their innovative approach and dedication to scientific excellence, they are paving the way for potential breakthroughs in cancer treatment. Join WNTresearch on their mission to fight cancer metastasis and improve the lives of those affected by this devastating disease